Table 3.
Estimated Impact of Lung Cancer Screening on Life-Years Saved and Cost per Life-Year Saved,a Using Base-Case (I-ELCAP Data for Screening Results)
| Impact of screening | Total | Male | Female |
|---|---|---|---|
| Cumulative life-years saved, yrs | 2,825,652 | 1,313,423 | 1,512,229 |
| Lead-time correction, yrs | 568,599 | 276,563 | 292,036 |
| True life-years saved (0-yr lead time life-year saved), yrs | 2,257,053 | 1,036,860 | 1,220,193 |
| Cumulative extra cost, $ | 41,647,811,614 | 23,241,454,701 | 18,406,356,913 |
| Cost per additional life-year, $ | 18,452 | 22,415 | 15,085 |
| Patients diagnosed with lung cancer in 2014 | |||
| Average life expectancy without screening, yrs | 3.07 | 2.81 | 3.36 |
| Average life expectancy with screening (with no lead time), yrs | 7.01 | 6.30 | 7.83 |
| Average increased life span because of screening, yrs | 3.94 | 3.49 | 4.47 |
a
Life-years saved and cost are for patients with cancer aged 55–110 years.
I-ELCAP indicates International Early Lung Cancer Action Program.
Source: Authors’ analysis.